172 economies are now involved in discussions to potentially participate in COVAX, a global vaccine-branded paint initiative to provide countries around the world with equitable access and effective vaccines once they are authorized and approved. COVAX has lately the world’s largest and most diversified COVID-19 vaccine portfolio, adding nine candidate vaccines, nine more in evaluation and ongoing discussions with others.
COVAX, the stick and pillar of the COVID-19 Tool Accelerator (ACT) vaccine, is co-directed through the Coalition for Innovations in Epidemic Preparedness (CEPI), Gavi, the Vaccine Alliance and the World Health Organization (WHO), in partnership with the vaccine. developed and emerging countries. It is the only global initiative working with governments and brands to ensure that COVID-19 vaccines are held internationally for the highest and lowest incomes.
In order to discharge enough doses of vaccines to protect the most vulnerable populations, such as fitness personnel and the elderly, the next step in the partnership is to verify the goal of potential self-funded participants to participate until August 31 and make them binding commitments to enroll in the COVID-19 Global Vaccine Access Mechanism (COVAX Center) through 18 September Of Array with the first initial bills to comply with from then on, and no later than 9 October 2020.
“Just as a COVID-19 vaccine is the key to defeating the virus and paving the way for the recovery of the pandemic,” Swedish Prime Minister Stefan Lefven said. “This cannot be a race with a few winners, and the installation of COVAX is a vital component of the solution, ensuring that all countries have the largest portfolio of applicants in the world and a fair and equitable distribution of vaccine doses.”
The COVAX facility is a joint procurement mechanism coordinated by Gavi for new COVID-19 vaccines, through which COVAX will ensure fair and equitable access to vaccines for each committed economy, using an allocation framework formulated through WHO. The COVAX facility will do this by pooling the purchasing force of committed economies and delivering volume promises through a variety of promising candidate vaccines, which will allow vaccine brands whose experience is essential for the large-scale production of new vaccines to be made early, large investments in production capacity , offering interested countries and economies the most productive opportunity to access doses of a successful COVID-19 vaccine.
COVAX’s good fortune is based not only on countries’ adherence to the COVAX facility, but also on filling key investment gaps for COVAX studies and progression tables and a mechanism for the participation of low-income economies in the COVAX facility.
“COVID-19 is an unprecedented global fitness challenge that can only be overcome through unprecedented cooperation between governments, researchers, brands and multilateral partners,” said Dr Tedros Adhanom Ghebreyesus, WHO Director-General. “By pooling resources and acting in solidarity through the ACT accelerator and COVAX facility, we can ensure that once you have a VACCINE for COVID-19, it will be obtained equally in all countries.
CEPI is leading the studies and progress of COVAX vaccines, which aim to expand 3 and the effective vaccines that can be made for countries participating in the COVAX facility. Recently, CEPI supports nine candidate vaccines; seven of which are lately in clinical trials. Governments, vaccine brands (in addition to their own studies and progression), organizations and Americans have so far committed US$1.4 billion for vaccine studies and progression, but another US$1 billion is urgently needed to further advance the portfolio.
Nine other candidate vaccines are currently being evaluated to complement CEPI’s existing portfolio for inclusion in COVAX. In addition, COVAX will buy vaccines that complement the portfolio of any manufacturer in the world; Discussions are already taking place with other brands that fail to achieve CEPI studies and the help of progression to unload their vaccines if they are lucky. Maximizing the vaccine portfolio increases the likelihood of good luck because individual vaccines have traditionally had a maximum failure rate.
“In vaccine fever, countries can act alone, creating a few winners and many losers, or they can join in COVAX, an initiative that is based on self-reported interest but also on equity, leaving no country behind,” said Richard Hatchett, CEO of CEPI. “Only by adopting a global vision will we be able to protect the world’s most vulnerable people from the terrible effects of this disease. COVAX can supply vaccines that can end the pandemic, but countries want to go ahead or enroll in COVAX Ease and to deal with serious investment deficits, adding up for studies and development. The decisions now being made regarding COVID-19 vaccines have the strength to replace our future. We will have to be courageous and ambitious in the search for a solution. »
A collaboration between the Serum Institute of India (SII), Gavi and the Bill and Melinda Gates Foundation announced earlier this month will ensure that up to one hundred million doses of AstraZeneca or Novavax candidate vaccines, if successful, will be available for low and medium savings earnings through the COVAX facility at just US$3 according to the dose. The fix also offers an option to download more doses if COVAX wishes. Separate agreements between Gavi, CEPI and AstraZeneca, announced in June, secure another three hundred million doses of your candidate vaccine, if successful, for COVAX facilities.
In addition, in June, Gavi introduced COVAX Advance Market Commitment (AMC), a funding tool to help the participation of 92 low- and middle-income countries in the COVAX line. COVAX AMC has raised more than US$600 million against an initial target of US$2 billion in initial investment from sovereign donors, as well as in philanthropy and the personal sector, needed until the end of 2020. Funding for COVAX AMC will be a barrier to access to COVID-19 vaccines is essential to have some ability to pay, a scenario that would leave the majority of the world’s population unprotected, the pandemic and its effect on relentless progress.
80 higher-income economies, which would fund vaccines with their own public budgets, have submitted interest statements before the August 31 deadline to confirm their intention to participate. They will marry 92 low- and middle-income countries that will receive support through the CMA if they meet their investment goals. Together, this organization of 172 countries represents more than 70% of the world’s population. Among the organization are representatives from all continents and more than one part of the global economies of the G20.
“The momentum behind this unprecedented global effort means that there can be a gentle at the end of the tunnel: a vaccine is our ultimate productive way to finish the acute phase of the pandemic and COVAX’s effort is the ultimate productive way to achieve this.” Dr. Seth Berkley, executive director of Gavi, the Vaccine Alliance, said. “For high-income countries, this is a win-win solution: not only will it have guaranteed access to the world’s largest vaccine portfolio, but it will also negotiate in a global consortium, reducing costs and effectively ensuring global access COVAX Facility membership gives each country its maximum productive opportunity to protect the most vulnerable members of its population , giving the world its maximum productive opportunity to mitigate the effect of this pandemic on people, communities and the world economy. To realize this vision from start to finish, we want countries to make commitments from start to finish: investment for studies and development, club in installation and help for COVAX AMC ».
The COVAX facility is coordinated through Gavi, the Vaccine Alliance, and is a key component of COVAX, the vaccine pillar of the AC Accelerator, an innovative global collaboration that involves vaccine brands to drive progression, production and equitable access to COVID-19 testing. , Treatments and Vaccines. The general purpose of COVAX is to drive the progress and manufacture of COVID-19 vaccines and to ensure fair and equitable access for all countries around the world. This will be achieved by sharing the dangers associated with vaccine progression and, if necessary, by investing in production from the outset so that vaccines can be deployed on a large scale as soon as they have been proven to be effective, and through the sharing of procurement and purchasing power. sufficient volumes to complete the acute phase of the pandemic until 2021.
The purpose of COVAX is until the end of 2021 to administer two billion doses and effective vaccines that have passed WHO regulatory approval and/or prequalification. These vaccines will be presented in a similar way to all countries involved, in proportion to their population, with priority for fitness personnel and then extended to vulnerable canopy groups, such as the elderly and other conditions with pre-existing conditions. Subsequently, new doses will be made based on the needs, vulnerability and threat of COVID-19 in the country. The COVAX facility will also have a dose buffer for humanitarian and emergency use, as well as dealing with severe outbreaks before they become uncontrollable.
———————————————
Notes for editors
All candidate vaccines supported by CEPI are as follows:
The nine candidate vaccines that are being recently evaluated for inclusion in COVAX facilities come with two from China, two from the United States of America, one from the People’s Republic of Korea, one from the United Kingdom of Great Britain and Northern Ireland and one global, multi-manufacturing association. Two of them are in test I phase, two are generation transfers and the rest are in the discovery stage. The 80 countries that submitted expressions of interest to the COVAX facility coordinated through Gavi come with 43 that have agreed to be publicly appointed: Andorra, Argentina, Armenia, Botswana, Brazil, Canada, Chile, Colombia, Croatia, Czech Republic, Dominican Republic, Estonia, Finland, Greece, Iceland, Iraq, Ireland, Israel, Japan, Jordan, Kuwait, Lebanon, Luxembourg, Mauritius, Mexico, South Africa, Monaco, Montenegro, New Zealand, Northern Macedonia , Norway, Palau Array Portugal, Qatar, People’s Republic of Korea, San Marino, Saudi Arabia, Seychelles, Singapore, Switzerland, United Arab Emirates, United Kingdom of Great Britain and Northern Ireland and Venezuela.
In July, Gavi’s Board of Directors agreed on the 92 savings that will gain advantages from COVAX’s Early Market Commitment (AMC). The full list is:
About Gavi, The Vaccine Alliance
Gavi, The Vaccine Alliance, is a public-private partnership that helps immunize some of the world’s young people who oppose some of the world’s deadliest diseases. Since its inception in 2000, Gavi has helped immunize an entire generation, more than 760 million young people, and saved more than thirteen million deaths, helping to halve child mortality in 73 emerging countries. Gavi also plays a key role in improving global fitness safety by supporting fitness systems and investing in global stocks of Ebola, cholera, meningitis and yellow fever vaccines. After two decades of progress, Gavi now focuses on protecting the next generation and the unvaccinated youth who are still behind, cutting-edge investments and the newest technologies, from drones to biometrics, to save millions more lives and prevent epidemics before they spread. countries of assistance on the road to self-sufficiency. Learn more about www.gavi.org and join us on Facebook and Twitter.
The Vaccine Alliance brings together emerging countries and donor governments, the World Health Organization, UNICEF, the World Bank, the vaccine industry, technical agencies, civil society, the Bill and Melinda Gates Foundation and other partners in the personal sector. See the full list of donor governments and other leading organizations that finance Gavi’s paintings here.
About CEPI
CEPI is a state-of-the-art partnership between public, private, philanthropic and civil organizations, launched at Davos in 2017, to expand vaccines and prevent long-term epidemics. CEPI acted urgently and in coordination with WHO in reaction to the emergence of COVID-19. CEPI has launched nine partnerships to expand vaccines opposed to the new coronavirus. Systems benefit from the immediate reaction platforms already supported through CEPI, as well as new partnerships.
Prior to the onset of COVID-19, previous PSYC diseases included Ebola, Lassa virus, Middle East Respiratory Syndrome coronavirus, Nipah virus, Rift Valley fever and Chikungunya virus. CEPI has also invested in platform technologies that can be used for vaccine and immunoprophylactic progression against unknown pathogens (disease X).
About who
The World Health Organization provides global leadership in public fitness within the United Nations system. Founded in 1948, WHO works with 194 Member States in six regions and more than 150 offices to publicize fitness, ensure some global protection and serve the most vulnerable. Our purpose for 2019-2023 is to make sure that one billion more people get universal fitness coverage, that another billion more people from fitness emergencies and provide a billion more people with better physical condition and well-being.
For COVID-19 updates and public health tips on coronavirus, visit www.who.int and follow WHO on Twitter, Facebook, Instagram, LinkedIn, TikTok, Pinterest, Snapchat, YouTube.
The good fortunes of COVAX are based not only on the adherence of countries to the COVAX facility, but also on filling the key investment gaps for COVAX studies and progression tables and a mechanism for the participation of low-income economies in the COVAX facility.
———————————————
Notes for editors
All candidate vaccines supported by CEPI are as follows:
The nine candidate vaccines that are being recently evaluated for inclusion in COVAX facilities come with two from China, two from the United States of America, one from the People’s Republic of Korea, one from the United Kingdom of Great Britain and Northern Ireland and one global, multi-manufacturing association. Two of them are in test I phase, two are generation transfers and the rest are in the discovery stage. The 80 countries that submitted expressions of interest to the COVAX facility coordinated through Gavi come with 43 that have agreed to be publicly appointed: Andorra, Argentina, Armenia, Botswana, Brazil, Canada, Chile, Colombia, Croatia, Czech Republic, Dominican Republic, Estonia, Finland, Greece, Iceland, Iraq, Ireland, Israel, Japan, Jordan, Kuwait, Lebanon, Luxembourg, Mauritius, Mexico, South Africa, Monaco, Montenegro, New Zealand, Northern Macedonia , Norway, Palau Array Portugal, Qatar, People’s Republic of Korea, San Marino, Saudi Arabia, Seychelles, Singapore, Switzerland, United Arab Emirates, United Kingdom of Great Britain and Northern Ireland and Venezuela.
In July, Gavi’s Board of Directors agreed on the 92 savings that will gain advantages from COVAX’s Early Market Commitment (AMC). The full list is:
About Gavi, The Vaccine Alliance
Gavi, the Vaccine Alliance, is a public-private partnership that helps immunize some of the world’s young people who oppose some of the world’s deadliest diseases. Since its inception in 2000, Gavi has helped immunize an entire generation (more than 760 million young people) and saved more than thirteen million deaths, helping to halve child mortality in 73 emerging countries. Gavi also plays a key role in improving global fitness safety by supporting fitness systems and investing in global stocks of Ebola, cholera, meningitis and yellow fever vaccines. After two decades of progress, Gavi now focuses on protecting the next generation and the unvaccinated youth who are still behind, cutting-edge investments, and the newest technologies, from drones to biometrics, to save millions more lives and save epidemics before they spread. countries of assistance on the road to self-sufficiency. Learn more about www.gavi.org and join us on Facebook and Twitter.
The Vaccine Alliance brings together emerging countries and donor governments, the World Health Organization, UNICEF, the World Bank, the vaccine industry, technical agencies, civil society, the Bill and Melinda Gates Foundation and other partners in the personal sector. See the full list of donor governments and other leading organizations that finance Gavi’s paintings here.
About CEPI
CEPI is a state-of-the-art partnership between public, private, philanthropic and civil organizations, launched at Davos in 2017, to expand vaccines and prevent long-term epidemics. CEPI acted urgently and in coordination with WHO in reaction to the emergence of COVID-19. CEPI has launched nine partnerships to expand vaccines opposed to the new coronavirus. Systems benefit from the immediate reaction platforms already supported through CEPI, as well as new partnerships.
Prior to the onset of COVID-19, previous PSYC diseases included Ebola, Lassa virus, Middle East Respiratory Syndrome coronavirus, Nipah virus, Rift Valley fever and Chikungunya virus. CEPI has also invested in platform technologies that can be used for vaccine and immunoprophylactic progression against unknown pathogens (disease X).
About who
The World Health Organization provides global leadership in public fitness within the United Nations system. Founded in 1948, WHO works with 194 Member States in six regions and more than 150 offices to publicize fitness, ensure some global protection and serve the most vulnerable. Our purpose for 2019-2023 is to make sure that one billion more people get universal fitness coverage, that another billion other people of fitness emergencies and provide one billion more people with better physical condition and well-being.
For UPDATES on COVID-19 and public health tips for yourself about coronavirus, visit www.who.int and follow WHO on Twitter, Facebook, Instagram, LinkedIn, TikTok, Pinterest, Snapchat, YouTube.
Learn more about the COVID-19 Tool Accelerator (ACT)
Standardization of coronavirus vaccines (COVID-19)
Questions and vaccine safety